Study guide

19.2 Medication Education, Informed Consent & Informed Refusal

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

19.2 Medication Education, Informed Consent & Informed Refusal

Key Takeaways Explain This Topic AI

The two highest-rated education activities in the 2025 practice analysis both concern medication information: intended effects and adverse events (index 11.05) and risks, benefits and outcomes enabling informed consent and refusal (index 10.43).

Informed consent requires disclosure of the nature of the treatment, risks and benefits, reasonable alternatives including no treatment, and confirmation that the patient has decisional capacity and is acting voluntarily.

Informed refusal requires the same disclosure process plus documentation of the specific consequences explained and the patient's stated reasons.

Patients on buprenorphine or methadone must be taught that opioid tolerance falls rapidly after discontinuation, making overdose risk after a lapse far higher than before treatment.

Off-label prescribing requires explicit disclosure that the agent lacks FDA approval for the indication, along with the magnitude of expected benefit and the alternatives.

Last updated: September 2026

19.2 Medication Education, Informed Consent & Informed Refusal

Quick Answer: The two highest-rated education activities in the ANCB practice analysis are both about medication: "provides healthcare consumers with information about intended effects and potential adverse events of proposed prescriptive treatments" (index 11.05) and "provides information on the risks, benefits, and outcomes of healthcare regimens to allow informed decision-making by the consumer, including informed consent and refusal" (index 10.43). Valid consent requires nature of treatment, risks, benefits, reasonable alternatives including no treatment, decisional capacity and voluntariness . Informed refusal requires the same process plus documentation of the specific consequences explained.

1. The Content of Medication Teaching

For every medication the APRN prescribes in addictions practice, cover seven elements:

Element Example for buprenorphine/naloxone

What it does and how "It sits on the same receptor as fentanyl but only partly turns it on, which stops withdrawal and craving without the high."

What to expect and when "Withdrawal should settle within an hour or two of the first dose. Craving usually drops over the first week."

How to take it "Let the film dissolve under your tongue. Don't chew or swallow it. No food or drink for 15 minutes before or during."

Common adverse effects Constipation, headache, sweating, dental problems from prolonged acidic contact — rinse with water after the film dissolves

Serious adverse effects and what to do Respiratory depression when combined with sedatives or alcohol; precipitated withdrawal if taken too soon after a full agonist

  • Interactions Benzodiazepines, alcohol, gabapentinoids, sedating antihistamines; CYP3A4 inhibitors and inducers
  • Missed dose and stopping What to do about a missed dose, and the tolerance-loss warning below
  • 2. The Tolerance-Loss Teaching Point

This is the single most life-critical piece of education in opioid use disorder care and it is frequently omitted.

Opioid tolerance falls rapidly after stopping methadone, buprenorphine, or after any period of abstinence — including incarceration, hospitalization, or residential treatment.

A dose the patient used comfortably before treatment can be fatal after two weeks away from opioids.

Overdose mortality is sharply elevated in the first two weeks after release from jail or prison and after discharge from residential treatment , precisely because of this mechanism.

Teaching script: "If you stop this medicine and later use again, do not use the amount you used to use. Your body has lost its tolerance. Use less, use with someone, and have naloxone. This is the conversation I most need you to remember."

Pair the teaching with a naloxone prescription at every transition , not only at initiation.

3. The Elements of Informed Consent

Element What must be established

Disclosure Nature of the proposed treatment; material risks; expected benefits; reasonable alternatives; the option of no treatment and its consequences

Understanding Confirmed by teach-back, not by signature

Capacity The patient can communicate a choice, understand the information, appreciate how it applies to their own situation, and reason about the options

Voluntariness Free of coercion. Court-mandated treatment complicates but does not eliminate voluntariness — the patient still consents to each specific intervention

Intoxication does not automatically negate capacity , and withdrawal does not automatically negate it either — but both require assessment at the time of decision rather than assumption. Capacity is decision-specific : a patient may lack capacity to decline life-saving surgery while retaining capacity to choose between buprenorphine and methadone.

4. Informed Refusal

When a patient declines a recommended treatment, the process is the mirror image of consent and must be documented with equal care:

Confirm the patient has capacity at the time of refusal.

Disclose the specific, concrete consequences of declining — not a generic warning. "Without medication, your risk of dying from an overdose in the next year is several times higher" rather than "this is dangerous."

Explore the reason . Most refusals reflect a correctable belief: a prior bad experience, stigma from a family member or mutual-help group, fear of "trading one drug for another," a cost or transportation barrier, or fear of losing custody.

Offer alternatives , including a lower-intensity option the patient will accept.

Leave the door open explicitly and document the invitation to return.

Record the patient's own words, the consequences explained, and the alternatives offered.

5. Off-Label Prescribing Disclosure

Much of addictions pharmacotherapy is off-label: topiramate and gabapentin for alcohol use disorder, naltrexone plus bupropion for methamphetamine use disorder, gabapentin for cannabis withdrawal, naltrexone for gambling disorder. The disclosure standard:

State plainly that the medication is not FDA-approved for this use .

Describe the actual strength of the evidence , including the size of the expected benefit.

Present alternatives , including approved treatments and non-pharmacological options.

Document the conversation. "Off-label use discussed" is insufficient; record what was said about evidence and alternatives.

6. Common Medication-Teaching Errors in Addictions Care

Error Correction

Telling a patient on extended-release naltrexone they simply "cannot get high" Teach that attempting to override the blockade with large opioid doses can be fatal, and that overdose risk rises sharply as the injection wears off

Failing to warn about precipitated withdrawal before buprenorphine induction Teach the required interval since last full-agonist use and what precipitated withdrawal feels like, so the patient can report it immediately

Omitting dental care teaching with sublingual buprenorphine Rinse with water after the film dissolves, delay brushing about an hour, maintain dental follow-up

Not discussing disulfiram's hidden alcohol sources Mouthwash, cooking wine, some sauces, hand sanitizer, certain cold preparations; and that sensitivity persists up to 14 days after the last dose

Assuming a signed consent form equals informed consent The form documents the process; teach-back demonstrates it